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ABSTRACT
Cervical cancer develops as a result of infection with high-risk human papillomavirus (HPV) through
persistent expression of early proteins E6 and E7. Our group pioneered a recombinant viral vector system
based on Semliki Forest virus (SFV) for vaccination against cervical cancer. The most striking benefit of this
alphavirus vector-based vaccine platform is its high potency. DNA vaccines on the other hand, have a
major advantage with respect to ease of production. In this study, the benefits associated with both SFV-
based vaccines and DNA vaccines were combined with the development of a DNA-launched RNA replicon
(DREP) vaccine targeting cervical cancer. Using intradermal delivery followed by electroporation, we
demonstrated that DREP encoding for E6,7 (DREP-E6,7) induced effective, therapeutic antitumor immunity.
While immunizations with a conventional DNA vaccine did not prevent tumor outgrowth, immunization
with a 200-fold lower equimolar dose of DREP (0.05 µg of DREP) resulted in approximately 85% of tumor-
free mice. To overcome the safety concern of potential malignant transformation at the vaccination site,
we evaluated the anti-tumor effect of a DREP vaccine encoding a shuffled version of E7 (DREP-E7sh). DREP-
E7sh delayed tumor growth yet not to the same extent as DREP-E6,7. In addition, inclusion of a helper
cassette and an ER targeting signal (sigHelp) did not significantly further enhance the suppression of
tumor outgrowth in the long term, albeit exhibiting better tumor control early after immunization.
Collectively, this study points towards the clinical evaluation of DREP encoding HPV antigens as a potent
immunotherapy for patients with HPV16 (pre)-malignancies.
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Cervical cancer is one of the most prominent causes of deaths
in women worldwide.1,2 The disease develops as a result of
persistent infection with high-risk human papillomavirus
(HPV) in (pre)malignant cervical intraepithelial lesions.3
HPV16, one of the most common high-risk subtypes, is
responsible for half of the global cervical cancer cases with
expression of early proteins E6 and E7 essential for cellular
transformation.4,5 Due to the persistent expression of these
oncoproteins in the tumor epithelia, they are ideal targets for
the various types of immunotherapeutic strategies developed
for HPV-induced malignancies.2
We previously explored the HPV-specific immunogenicity
of a Semliki Forest virus-based cancer vaccine vector (VREP)
encoding a fusion protein of HPV16 E6 and E7.6 This plat-
form resulted in 100% anti-tumor efficacy in pre-clinical
studies providing a promising immunotherapeutic strategy
in the clinic.7 The potency of this SFV-based replicon particle
strategy stems from the intrinsic adjuvant property of the
encoded replicase. The replicase is responsible for the self-
replication of the introduced recombinant alphaviral RNA in
the infected cell. The replicase activity and the amplification
of RNA results in intermediates that are recognized by pattern
recognition receptors (PRR). Stimulation of PRR leads to a
high production of type I interferon.8,9 Likely the antigenicity
of the replicase is also partly due to the expression of strong
helper epitopes. Subsequent to the antigen production, apop-
tosis of the infected cells is induced leading to activation of
dendritic cells resulting in CD8 + T cell responses.10,11 As the
production of these VREP particles for clinical use is labor-
ious, we aimed to combine its inherent potency with the
advantages associated with DNA vaccines.12
Conventional DNA vectors have been poorly translated to
humans with most clinical data demonstrating only weak to
modest responses. Hence, several efforts have been made to
improve the potency of DNA vectors. These efforts include
increasing the transfection frequency in vivo13,14 most notably
using DNA electroporation (EP).15 The EP procedure itself
induces inflammation while being safe and tolerable. EP
further improves the potency of DNA vectors with adminis-
tration in the skin. The skin is populated with antigen-pre-
senting cells such as Langerhans cells and dermal dendritic
cells for efficient priming of naïve CD8+ T cells. We have
demonstrated higher intrinsic immune efficacy of our VREP
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vaccine via delivery in the skin as compared to the intramus-
cular (i.m.) route.16,17
Another way to enhance the potency of DNA vaccination
is in the vector itself. For instance, we and others have con-
structed DNA vectors based on the replicase of alphaviruses
such as Semliki Forest virus (SFV), Sindbis virus and
Venezuelan equine encephalitis virus (VEE). These DNA
replicon (DREP) vectors have been shown to elicit T cell
responses superior to those of conventional plasmid DNA in
preclinical studies against infectious agents such as human
immunodeficiency virus or chikungunya virus.18,19 This has
also been demonstrated within the context of cancer
vaccination.20,21 Nevertheless, to date, no SFV-based DNA
replicon vaccine has been explored as an alternative for
VREP for eliciting effective anti-tumor immunity.
In this study, we developed an SFV-based DREP vaccine
against HPV-induced cancers. We compared the in vivo
immunogenicity of our DREP vaccine with that of conven-
tional DNA in naïve and tumor-bearing mice using intrader-
mal (i.d.) EP as a delivery method. This promising next-
generation vaccine exhibited superior dose-sparing effects
with up to a 1000-fold lower dose (0.05 µg versus 10–50 µg)
required to elicit potent tumor immunity compared to the




Two types of plasmids encoding HPV proteins were used in
this study (Figure 1). The first, pVAX1, is a conventional
plasmid used in the development of DNA vaccines where the
expression cassette is under the control of a cytomegalovirus
(CMV) promoter. The second type is an SFV-based DNA-
launched RNA replicon (DREP) vaccine encoding the SFV
replicase, where the transcription of the viral replicon is
under the control of a CMV promoter and where the mRNA
encoding for the foreign antigens is expressed from an internal
viral promoter on the replicon RNA. These vectors were con-
structed to express an E6,7 fusion protein. Since chromosomal
integration could be a safety concern in connection with DNA
vaccination, we additionally constructed a DREP vector expres-
sing a shuffled E7 (E7sh) protein. The shuffled version of E7
loses its transforming potential but retains relevant T cell
epitopes.22 To potentially further enhance the immunogenicity
of DREP, we included in the construct a universal “helper-
cassette” with a series of T-helper epitopes as previously
described (Help).23 A human growth hormone signal peptide
and a KDEL sequence was also added to achieve ER localiza-
tion and retention (sig).23 The KDEL sequences prevents the
antigen from being secreted from the ER.23 In previous work,
within the context of HPV viral vector and DNA vaccination,
we have demonstrated increased anti-HPV immunity by inclu-
sion of sigHelp.24
Potent immunotherapeutic effect of DREP over
conventional DNA
First, we evaluated the intrinsic adjuvant property of the SFV
replicase in our DNA vaccine and compared it to conven-
tional plasmid DNA lacking the replicase. The replicase drives
the amplification of replicon RNA that includes the antigen of
interest. As a result, a large amount of antigen is produced. To
demonstrate the enhanced expression of the transgene, E6,7,
we transfected BHK-21 with either pVAX-E6,7 or DREP-E6,7
(Supplementary Figure 1). Expression of E6,7 was analyzed
using flow cytometry 24 hours after transfection using an
antibody targeting E7. pVAX-Luc and DREP-Luc were used
as negative controls. The percentage of cells transfected with
pVAX-eE6,7 and DREP-E6,7 were 8.1% and 21.1%, respec-
tively. On a per cell basis, the expression of E6,7 was 2.5-fold
higher in cells transfected with DREP-E6,7. As DREP is
approximately 3x larger than pVAX, transfection with DREP
results in a 7.5-fold higher expression level on a per mole
basis. Hence, we demonstrate that DREP strongly enhances
the expression of our antigen of interest.
Next, we determined whether the immunostimulatory prop-
erties of DREP enhances HPV-specific immunity of DREP-
E6,7 above that of pVAX-eE6,7. A preferred route of immuni-
zation for DNA vaccines is the intradermal (i.d.) route aided by
in vivo EP. For DREP, we have previously shown superior
responses against viral targets using EP compared to intrader-
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Figure 1. DNA vectors. Schematic representation of conventional (pVAX1) and replicon DNA (DREP) vectors and corresponding antigens (E6,7 or E7sh). CMV,
cytomegalovirus promoter; 26S, subgenomic 26S promoter.
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this study. We immunized mice twice with an equimolar
amount of DREP and pVAX (10 and 3.2 μg, respectively)
with a 20-day interval. E7-specific responses were evaluated
in splenocytes 7 days after the last immunization. At 10 ug,
DREP induces a significantly higher percentage of E7-specific
CD8+ T cells and higher number of IFN-γ-producing cells
compared to pVAX immunization (Figure 2a,b).
Given the enhanced E7-specific immunogenicity of DREP,
we subsequently determined the therapeutic effect of DREP-
E6,7 using an HPV tumor model (TC-1) (Figure 2c,d). Mice
were immunized with DREP or pVAX 7, 14 and 21 days after
TC-1 inoculation. In this model, palpable tumors develop
approximately 14 days post inoculation. In non-vaccinated
mice, tumors grow exponentially from that point onward to
approximately 1000 mm3 3–4 weeks after inoculation. Due to
the exponential growth of these tumors immunizations need to
be scheduled weekly. This may not be the preferred schedule
for replicon vaccines. We previously demonstrated that weekly
injection of replicon vaccines (before contraction of the
CD8 + T cell response), results in lower memory responses.18,25
Hence we could speculate that the frequent injections as well as
the high dose could synergistically weaken the immune
response. Immunization with 3.2 µg of pVAX resulted in the
same tumor growth pattern as for non-vaccinated mice. An
equimolar dose of DREP (10 µg) induced a significant delay in
tumor growth, with approximately 43% of mice remaining
tumor-free by day 60. We additionally included a group receiv-
ing a dose of 20 µg of pVAXeE6,7 as Oosterhuis et al. had
applied, yet this also resulted in tumor outgrowth as seen in
control mice (data not shown).23 Hence, the enhanced immu-
nogenicity with DREP also translated to effective anti-tumor
immunity in this fast growing HPV tumor model.
Previous studies using DREP have also observed potent
immunogenicity with doses lower than 10 µg. Reducing the
dose 125 times (from 10 μg to 0.08 μg) demonstrated no
significant loss of T cell responses.18 Moreover, dosages higher
than 10 μg results in lower antigen-specific responses.18,25 For
this reason, we also evaluated the anti-tumor effect of DREP at
doses lower than 10 μg. Using the same schedule after tumor
inoculation, we immunized mice with 0.2 and 0.05 μg of DREP.
With all doses, there was a significant delay in tumor growth
compared to pVAX or PBS control starting at 20 days post
tumor inoculation (Figure 2d). Immunization with either dose
resulted in a similar survival rate (Figure 2e). One week after
the last immunization, the percentage of E7-specific T cells was
determined in blood, and although there was an observable, yet
insignificant increase in E7-specific T cells with a high dose (10
ug), this increase was reversibly correlated with anti-tumor
control (Figure 2f).
The inclusion of sigHelp-KDEL enhances the frequency of
HPV-specific T cells but doesn’t further enhance in vivo
anti-tumor effects
We next assessed whether inclusion of sigHelp-KDEL, a series
of helper T cell epitopes and an ER targeting signal, enhances
the immunogenicity of DREP. Mice were immunized twice
with 10 µg of DREP. E7-specific responses were evaluated in
splenocytes 9 days after the last immunization. At 10 µg,
DREP-sHelpE6,7 induces a significantly higher percentages
of E7-specific CD8+ T cells and a higher number of IFN-γ-
producing cells compared to DREP-E6,7 (Figure 3a,b).
We next determined whether the inclusion of sigHelp
enhancing the anti-tumor effect DREP to achieve possibly
100% of tumor-free mice (Figure 3c). We immunized mice
with 0.2 µg of DREP with the same TC-1 model. Significant
tumor control above that of the buffer control was achieved at
a dosage of 0.2 µg for both DREP constructs. Inclusion of
sHelp-KDEL did not significantly delay tumor growth in
DREP-E6,7 resulting in similar survival rates (Figure 3d,e).
This was also the case for a dosage of 0.05 µg (Supplementary
Figure 2). However, albeit not significant, there is an obser-
vable decrease in the initial outgrowth of tumors with inclu-
sion of sHelp-KDEL demonstrating early control by induced
HPV immunity.
Previous studies have demonstrated prolonged survival
with inclusion of sHelp-KDEL for conventional DNA vacci-
nation targeting another HPV antigen.23 This antigen, devel-
oped by Ohlschlager et al., is a shuffled version of E7 (E7sh)
to avoid the risk of cellular transformation at the vaccination
site.22 We wanted to assess whether inclusion of sHelp-KDEL
could also enhance immunity compared to DREP-E7sh. Naïve
mice were immunized with 10 μg of either DREP-sHelpE7sh
or DREP-E7sh (Figure 4a,b). The frequency of E7-specific
CD8+ T cells in spleen was assessed at day 9 after the last
immunization. At this point a trend toward an increased
frequency of E7-specific T cells and number of IFN-γ-produ-
cing cells was observed for DREP-sHelpE7sh. The anti-tumor
effect upon inclusion of sHelp-KDEL in DREP-E7sh was
further assessed. Mice were immunized with 0.2 and 0.05 µg
of DREP encoding E7sh with the same schedule as above
using the TC-1 model (Figure 4c,d). DREP-sHelpE7sh
resulted in tumors that regressed around day 20 with 57%
and 43% of the mice being tumor-free with doses of 0.2 and
0.05 μg, respectively. This is in contrast to immunization with
DREP-E7sh with suppression of tumor growth only achieved
in 29% and 14% of mice immunized with doses of 0.2 and
0.05 μg, respectively (Figure 4c). At 28 days post tumor
inoculation, there is a significant control of tumor outgrowth
by all DREP constructs compared to PBS control. This was
also the case for DREP-sHelpE7sh compared to DREP-E7sh at
a dose of 0.05 ug (Figure 4d). Despite this observation, the
delay in survival was insignificant between the two matched
dose groups (Figure 4e).
Discussion
In this study, we demonstrated potent therapeutic anti-
tumor efficacy provided by a DNA replicon vector with
doses as low as 0.05 µg. This is a 1000-fold lower dose as
compared to most studies using conventional pDNA as
application in cancer immunotherapy. Additionally, in this
work, we are the first to develop a replicon DNA vaccine
candidate based on Semliki Forest virus targeting HPV. Our
SFV DNA-launched RNA replicon, encoding a stable fusion
protein of HPV oncogenes E6 and E7 delivered by in vivo
electroporation resulted in approximately 85% of mice
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Figure 2. HPV-specific immunity and therapeutic effect by DREP-E6,7 over conventional DNA. C57BL/6 mice (n = 3–4 per group) were immunized i.d. followed
by EP at a 20-day interval with DREP-E6,7 at 10 µg or an equimolar dose of pVAX-E6,7 (3.2 µg). Phosphate buffered saline (PBS) was injected as a negative
control. Seven days after the boost mice were sacrificed and spleens were isolated for assessment of percentages of E7-specific CD8+ T cells and the number
of IFN-γ-producing cells with dextramer staining (A) and ELISpot analysis (B), respectively. For assessment of therapeutic effect, C57BL/6 mice were inoculated
s.c. with 2 × 104 TC-1 and mice were immunized i.d. followed by EP on days 7, 14 and 21. Doses include 10, 0.2 or 0.05 µg for DREP and 3.2 µg for pVAX.
Tumors were palped twice a week for 62 days. The individual growth curves for each corresponding group is depicted in (C) and the average tumor sizes and
standard error of the mean per group until day 28 is shown in (D). The group size and number of mice that are still alive at day 62 are indicated in the
numbers in each panel. The survival percentages are depicted in (E). The results (C-E) are pooled from two separate experiments of 7 mice/group resulting in
a total of 14 mice. Blood was drawn from 3–4 mice for assessment of E7-specific CD8 + T cells with dextramer staining in mice immunized with DREP one
week after the last immunization. As a cut-off for positivity for E7-specific T cells, we collected blood from mice that were still alive in the PBS control (N = 1)
and pVAX group (N = 2) at that time point (F). *P < 0.05; **P < 0.01; ***P < 0.001.
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The high immunogenicity of DREP over that of conven-
tional pDNA (pVAX) is most likely due to the self-amplifying
nature of the SFV replicase, resulting in high copies of viral
RNA transcripts for stimulation of innate immunity.9,26,27 The
replicase also produces 5ʹ-triphosphate dsRNA of non-viral
host cell RNA templates.28 The RNA transcripts signal innate
immunity through RNA sensing by Toll-like receptor 3
(TLR3), TLR7, TLR8, MDA-5, RIG-I and protein kinase R
for a type I IFN response.28 The type I IFN response induces
T cell memory responses with the alphaviral replicase indu-
cing apoptosis in targeted cells which in turn is taken up by
dendritic cells, favoring antigen spreading and stimulating
cross-presentation for adaptive immunity.29,30 The potent
anti-tumor effect of DREP is likely also attributable to
enhanced in vivo delivery using EP previously shown to be
superior above others in the case of HPV vaccination.31,32
Intradermal administration of DREP-E6,7 with in vivo EP
significantly increased E7-specific T cell frequencies above
that of pVAX. The immunogenicity of the two DNA vectors
was compared with equivalent molar doses administered.
However, as seen by others pVAX was also not immunogenic
at a dose of 10 µg or less, regardless of the administration
method. 23,33 In those studies there were also no detectable
responses observed with repeated administrations of 20 µg of
pVAX, with anti-tumor control only demonstrated within the
context of an optimized DNA vector.23
The tumor growth was significantly delayed when immuniz-















































































































































Figure 3. Inclusion of sigHelp on HPV-specific immunity and therapeutic effect by DREP-E6,7. C57BL/6 mice (n = 3 per group) were immunized i.d. followed by EP at
a 20-day interval with 10 µg of DREP-eE6,7 or DREP-sHelpE6,7. Phosphate buffered saline (PBS) was injected as a negative control. Seven days after the boost mice
were sacrificed and spleens were isolated for assessment of percentages of E7-specific CD8+ T cells and number of IFN-γ-producing cells with dextramer staining (A)
and ELISpot analysis (B), respectively. For assessment of therapeutic effect, C57BL/6 mice (n = 7 per group) were inoculated s.c. with 2 × 104 TC-1 and mice were
immunized i.d. followed by EP on days 7, 14 and 21. DREP was administered as a dose of 0.2 µg. Tumors were palped twice a week for 108 days. The individual
growth curves for each corresponding group is depicted in (C) and the average tumor sizes and standard error of the mean per group is shown in (D) until day 28.
The group size and number of mice that are still alive at day 108 are indicated in the numbers in each panel. The survival percentages are depicted in (E). *P < 0.05;
**P < 0.01; ***P < 0.001.
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stronger anti-tumor efficacy with as low as 0.05 µg with 85% of
mice remaining tumor-free by the last palpation. This observed
inverse correlation between dose and immunogenicity of alpha-
viral DNA replicons is not unprecedented, as it has been pre-
viously observed in other studies with type I IFNs halting the
production and amplification of the replicon due to their effect
on cells undergoing an antiviral state.8,18 This decreased immu-
nogenicity was observed for both humoral and cellular immune
responses.18,34 Interestingly, upon assessment for frequencies of
E7-specific T cells in blood, we hadn’t observed a significant
difference between the different doses used. It is possible that the
magnitude is not indicative of better tumor control. This con-
clusion was also made in one recent study using the TC-1 tumor
model and vaccination with conventional DNA encoding
E7sh.35 The authors achieved 100% survival by combining vac-
cination with CD27 agonism and programmed death receptor 1
(PD1) blockade.35 At day 15 after tumor inoculation, the com-
bined treatments resulted in approximately 20% of E7-specific T
cells compared to 60% with replacing PD1 blockade with cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4). However,
CTLA-4 blockade with CD27 agonism and vaccination resulted
in half of mice surviving by day 100. It would be of interest to
determine a better correlate of therapeutic efficacy. In addition,
the immunization schedule in the TC-1 tumor model includes
three injections at a one-week interval as dictated by the fast
growth of the tumor. In a previous study, we have demonstrated
that boosting at a short interval of 1 week with replicon SFV
significantly decreased cellular immunity.25 It may be that injec-
tion of a short interval further decreases the strength of the
immune response, yet this affects memory rather than acute
responses. This decrease is not likely a result of vector-specific
immune responses as we previous demonstrated in a study using
an homologous prime-boost immunization with rSFV.36 Other
studies have also demonstrated that multiple booster immuniza-
tions do not result in weaker immune responses and no vector-









































































































































































Figure 4. Inclusion of sigHelp on HPV-specific immunity and therapeutic effect by DREP-E7sh. C57BL/6 mice (n = 3 per group) were immunized i.d. followed by EP at a 20-
day interval with 10 µg of DREP-E7sh or DREP-sHelpE7sh. The negative control from Figure 3 was also used within this experiment. Seven days after the boost mice were
sacrificed and spleens were isolated for assessment of percentages of E7-specific CD8+ T cells and number of IFN-γ-producing cells with dextramer staining (A) and ELISpot
analysis (B). For assessment of therapeutic effect, C57BL/6 mice (n = 7 per group) were inoculated s.c. with 2 × 104 TC-1 and mice were immunized i.d. followed by EP on
days 7, 14 and 21. DREP was administered at a dose of 0.2 or 0.05 ug. Tumors were palped twice a week for 108 days. The individual growth curves for each corresponding
group is depicted in (C) and the average tumor sizes and standard error of the mean per group is shown in (D) until day 28. The group size and number of mice that are still
alive at day 108 are indicated in the numbers in each panel. The survival percentages are depicted in (E). *P < 0.05; **P < 0.01; ***P < 0.001.
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backbone used.37,38 Rather than themagnitude, the quality of the
CD8 + T cell response may correlate with effective tumor
control.39 It was observed that increasing the dose of replicon
particles favored T effector memory (Tem) development and
inhibited T central memory (Tcm) formation.25 This may have
implications within the context of tumor immunity as Tcm cells
possess recall proliferation capacity that are required for effective
anti-tumor control.40,41 It has also been previously observed that
homologous SFV replicon immunization results in better tumor
control over homologous adenovirus immunization or hetero-
logous immunization due to a favored central memory T cell
response.39,42 It would also be of value to determine whether this
decrease is due to T cell exhaustion and hence, assessment
of exhaustion markers, such as programmed death protein 1
(PD-1) is warranted.
Removal of the transforming potential of oncogenes,
such as of E6 and E7, is a prerequisite before applying
DNA vaccines in particular in the clinic. For this purpose,
a “shuffled” version of E7 was incorporated into DREP
and compared with that of DREP-E6,7 in terms of immu-
nogenicity. Again, despite the lower E7-specific CD8 + T
cells observed in spleen with E6,7 compared to E7sh, the
former presented with better tumor control. The greater
anti-tumor control by DREP-E6,7 is likely due to both E6
and E7 responses for optimal anti-tumor effect as is the
case for SFV VREP encoding E6 and E7. In a preclinical
study with SFV replicon particles we also demonstrated
higher anti-tumor immunity with the inclusion of both E6
and E7 compared to either oncogene alone.43
Furthermore, in patients with HPV neoplasia both E6
and E7-specific CD8 + T cell responses have been corre-
lated with better prognostic value.44 Despite the lower
immunogenicity observed with the variant of E7, admin-
istration of either a 0.2 or 0.05 ug dose of E7sh resulted in
a significant delay in tumor growth compared to the con-
trol group. This is in contrast to a previous study on
pVAX encoding E7sh, with no responses detected with as
high dosages as 20 ug.23 The low immunogenicity of
pVAX-E7SH is rescued in these studies with the addition
of helper epitopes and a retention signal with insertion of
SigHelp-KDEL.33 In a previous study using VREP parti-
cles, the insertion of SigHelp-KDEL resulted in a higher
percentage of E7-specific effector T cells at both early and
late time points after immunization.24 Significant differ-
ences in the effector memory T cell phenotype was only
significantly higher early after immunization.24 In this
study, we observed an increase in anti-tumor effect with
inclusion DREP-sHelpE7SH, which was not the case for
DREP-sHelpE6,7. This may be due to the high threshold
of response set by both E6 and E7. Although it is difficult
to compare this finding with the study of Oosterhuis et al.-
23 given the different delivery methods, we nevertheless
demonstrate significant anti-tumor efficacy at a 100x-
lower dose of DNA upon inclusion of the SFV replicase.
In conclusion, we generated DNA-based SFV replicon vac-
cines which are able to elicit potent HPV-specific anti-tumor
responses with unprecedented low dosages of DNA. This DNA
replicon strategy could pave the way for clinical translation of
vaccines applicable to a wide range of target antigens.
Materials and methods
DNA vectors
The plasmids that were used in this study are either that of
conventional DNA (pVAX 1) or a DNA-launched RNA repli-
con (DREP) encoding HPV oncogenes E6 and/or E7. Encoded
in the plasmids is foot-and-mouth disease virus 2A autopro-
tease inserted after the translational enhancer consisting of the
first 34 amino acids of the capsid (e).45 For the generation of
pVAX-E6,7, the sigE7KDEL fragment was removed from
pVAX1sigE7KDEL (kindly provided by Prof. T Schumacher
(The Netherlands Cancer Institute The Netherlands)) by diges-
tion with PmeI (producing PmeI-pVAX1-PmeI). pUC19e-E6,7
served as a template, digested with SmaI and HincII producing
SmaI-eE6,7-HincII and treated with FastAp Alkaline
Phosphatase to prevent self-ligation. SmaI-eE6,7-HincII was
ligated into pVAX1 to produce pVAX-E6,7. For construction
of pVAXeLuc, pVAXeE6,7 and pSFV3eLuc plasmids were
used. These constructs were digested with ApaI and XbaI.
ApaI-eLuc-XbaI from pSFV3 was cloned into XbaI-pVAX-
ApaI to produce pVAXeLuc. DREP-OVA served as a template
to produce DREP-Luc and DREP-E6,7. DREP-Luc was con-
structed by cloning Luc from pSFV3eLuc via digestion of both
plasmids with ApaI and XmaI. DREP-E6,7 was constructed by
cloning eE6,7 from pSFV20eE6,7 digestion of both plasmids
with HindIII and NotI. DREP-E6,7 was used for the construc-
tion of all remaining DREP plasmids. DREP-E7sh was con-
structed by cloning the NotI-E7SH-XmaI fragment from the
construction of pSFVeE7SH, as previously described.24 The
E7SH fragment was inserted into DREP upon removal of
E6,7 by SmaI and PspOMI digestion. The DREP backbone
was additionally ligated with sigHELP-E6,7-KDEL or
sigHELP-E6,7-KDEL to create DREP-sHelpE6,7 or DREP-
sHelpE7sh, respectively. The ligated inserts were both obtained
from pVAX plasmids encoding either of the two antigens23 by
NotI and SmaI digestion upon introduction of these restriction
sites with PCR. All restriction enzymes were purchased from
Thermo Scientific. All plasmids were expressed and amplified
in E.coli NEB10b 10, purified by an endotoxin-free DNA pur-
ification kit (Qiagen) and dissolved in phosphate-buffered sal-
ine (PBS) (Gibco, Invitrogen) and digested by enzyme
restriction to confirm the correct size of the antigen. The
constructs were further confirmed by sequencing.
Cell lines
Baby hamster kidney cells (BHK-21) were obtained from the
American Type Culture Collection (No. CCL-10). TC-1
tumor cells, transformed with a retroviral vector expressing
HPV16 E6E7, and C3, expressing the complete HPV16 gen-
ome, were received as a kind gift from Prof. C. Melief (Leiden
University Medical Center, The Netherlands). These cells
were cultured as previously described.24
Quantification of E7-expressing cells
BHK-21 cells were transfected with 10 ug of DNA at a ratio of
1:4 with lipofectamine2000 according to the manufacturer’s
ONCOIMMUNOLOGY e1487913-7
instructions. Cells were harvested 24 hours later and stained
with LIVE/DEAD fixable violet dead cell stain kit (Life tech-
nologies) according the manufacturer’s manuals. This was
followed with an intracellular staining using a primary anti-
body targeting HPV16-E7 (clone 8C9) and subsequently sec-
ondary goat anti-mouse (H + L) AlexaFluor647 (Life
Technologies). FACS analysis was performed with LSR-II
flow cytometer (BD Bioscience) and data analyzed using
FlowJo analysis software (Tree Star).
Mice and immunizations
Female inbred C57BL/6J (H-2b) female mice were bred at the
Department of Microbiology, Tumor and Cell Biology, at the
Karolinska Institutet or purchased from Scanbur Research. All
mice were 8 to 10 weeks of age at the start of all experiments and
immunized i.d. with in vivo EP as previous described.18 For
assessment of immunogenicity, mice were primed and boosted
with 10 ug of DREP or 3.2 ug of pVAX (equimolar amounts).
For assessment of anti-tumor efficacy mice were immunized
three times at one week intervals at various indicated doses.
Mouse splenocyte isolation
This procedure was performed as previously described.25
Blood lymphocyte isolation
Mice were bled from the tail vein and blood was collected in
tubes containing heparin. Samples were lysed with red blood
cell lysis buffer for 5 min after which 10 mL addition of
complete RPMI medium (RPMI 1640 supplemented with 5%
fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin (all from Gibco or Invitrogen). Then
samples were centrifuged at 400 X g for 5 min, and each cell
pellet was resuspended in 200 uL of complete RPMI medium.
Quantification of E7-specific cells
Splenocytes or peripheral blood collected from the tail vein
were subjected to erythrocyte lysis and stained with PE-
RAHYNIVTF-dextramers (Immudex) and PE-Cy7-anti-
CD8a Ab (clone: 53–6.7) according to manufacturer’s proto-
col. FACS analysis was performed with LSR-II flow cytometer
(BD Bioscience) and data analyzed using FlowJo analysis soft-
ware (Tree Star, Ashland, OR).
IFN-γ elispot assay
This assay was performed as previously described.18 In
brief, MultiScreen-IP plates (Millipore) were activated with
70% ethanol and coated overnight with anti-IFN-gamma
antibodies (AN18; Mabtech) 4°C. After washing with PBS,
plates were blocked with complete RPMI medium for
approx. 2 h at 37°C. Freshly isolated spleen cells then
replaced the blocking medium at 0.2 million cells per well
and were stimulated in triplicate with either 2 ug/ml of the
E7-derived peptide (RAHYNIVTF, H-2Db) (Proimmune) or
medium alone. Concanavalin A (Sigma-Aldrich) at 2 ug/ml
in duplicates was used as a positive control. Plates were
incubated at 37°C with 5% CO2 for 20 ± 2 h and developed
as recommended by the manufacturer using biotinylated
anti-IFN-gamma detector antibody (R4-6A2), streptavidin-
alkaline phosphatase, and BCIP-NBT Plus substrate
(Mabtech). Spots were counted using an ImmunoSpot ana-
lyzer and ImmunoSpot software (Cellular Technology) and
multiplied by 5 to represent the number of spots/1 million
cells.
Tumor inoculation
Mice were inoculated subcutaneously (s.c.) with 2 × 104 TC-1
cells expressed both HPV16 E6 and E7 suspended in 0.2 ml
PBS. Tumor volume was determined using a caliper per-
formed by the same skilled technician twice per week starting
at day 7. Mice were sacrificed once the tumor volume
exceeded 1000 mm3.
Statistical analysis
Analysis was performed using GraphPad Prism software. For
comparison between two groups, the Mann-Whitney U test
was used. For analysis of differences between survival curves,
log-rank (Mantel-Cox) test was used. Two-way ANOVA with
Bonferroni post-test was used for comparison of tumor
growth curves at different time points. A P < 0.05 is consid-
ered statistically significant.
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